Search

Your search keyword '"Rodolfo, Monica"' showing total 383 results
Start Over Author "Rodolfo, Monica"
383 results on '"Rodolfo, Monica"'

1. Comprehensive genomic profiling on metastatic Melanoma: results from a network screening from 7 Italian Cancer Centres

Author

Pallocca, Matteo, Molineris, Ivan, Berrino, Enrico, Marcozzi, Benedetta, Betti, Martina, Levati, Lauretta, D’Atri, Stefania, Menin, Chiara, Madonna, Gabriele, Ghiorzo, Paola, Bulgarelli, Jenny, Ferraresi, Virgina, Venesio, Tiziana, Rodolfo, Monica, Rivoltini, Licia, Lanfrancone, Luisa, Ascierto, Paolo Antonio, Mazzarella, Luca, Pelicci, Pier Giuseppe, De Maria, Ruggero, Ciliberto, Gennaro, Medico, Enzo, and Russo, Giandomenico

Published
2024
Full Text
View/download PDF

3. Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles

Author

Vergani, Elisabetta, Busico, Adele, Dugo, Matteo, Devecchi, Andrea, Valeri, Barbara, Cossa, Mara, Di Guardo, Lorenza, De Cecco, Loris, Feltrin, Erika, Valle, Giorgio, Deho, Paola, Frigerio, Simona, Lalli, Luca, Gallino, Gianfrancesco, Del Vecchio, Michele, Santinami, Mario, Pruneri, Giancarlo, Tamborini, Elena, Rivoltini, Licia, Sensi, Marialuisa, Vallacchi, Viviana, and Rodolfo, Monica

Published
2022
Full Text
View/download PDF

5. MC1R variants in childhood and adolescent melanoma: a retrospective pooled analysis of a multicentre cohort

Author

Pellegrini, Cristina, Botta, Francesca, Massi, Daniela, Martorelli, Claudia, Facchetti, Fabio, Gandini, Sara, Maisonneuve, Patrick, Avril, Marie-Françoise, Demenais, Florence, Paillerets, Brigitte Bressac-de, Hoiom, Veronica, Cust, Anne E, Anton-Culver, Hoda, Gruber, Stephen B, Gallagher, Richard P, Marrett, Loraine, Zanetti, Roberto, Dwyer, Terence, Thomas, Nancy E, Begg, Colin B, Berwick, Marianne, Puig, Susana, Potrony, Miriam, Nagore, Eduardo, Ghiorzo, Paola, Menin, Chiara, Manganoni, Ausilia Maria, Rodolfo, Monica, Brugnara, Sonia, Passoni, Emanuela, Sekulovic, Lidija Kandolf, Baldini, Federica, Guida, Gabriella, Stratigos, Alexandros, Ozdemir, Fezal, Ayala, Fabrizio, Fernandez-de-Misa, Ricardo, Quaglino, Pietro, Ribas, Gloria, Romanini, Antonella, Migliano, Emilia, Stanganelli, Ignazio, Kanetsky, Peter A, Pizzichetta, Maria Antonietta, García-Borrón, Jose Carlos, Nan, Hongmei, Landi, Maria Teresa, Little, Julian, Newton-Bishop, Julia, Sera, Francesco, Fargnoli, Maria Concetta, Raimondi, Sara, Group, IMI Study, Alaibac, Mauro, Ferrari, Andrea, Valeri, Barbara, Sicher, Mariacristina, Mangiola, Daniela, Nazzaro, Gianluca, Tosti, Giulio, Mazzarol, Giovanni, Giudice, Giuseppe, Ribero, Simone, Astrua, Chiara, Mazzoni, Laura, Group, GEM Study, Orlow, Irene, Mujumdar, Urvi, Hummer, Amanda, Busam, Klaus, Roy, Pampa, Canchola, Rebecca, Clas, Brian, Cotignola, Javiar, Monroe, Yvette, Armstrong, Bruce, Kricker, Anne, Litchfield, Melisa, Tucker, Paul, Stephens, Nicola, Switzer, Teresa, Theis, Beth, From, Lynn, Chowdhury, Noori, Vanasse, Louise, Purdue, Mark, Northrup, David, Rosso, Stefano, Sacerdote, Carlotta, Leighton, Nancy, Gildea, Maureen, Bonner, Joe, Jeter, Joanne, Klotz, Judith, Wilcox, Homer, Weiss, Helen, Millikan, Robert, Mattingly, Dianne, and Player, Jon

Subjects
Clinical Research, Pediatric, Genetics, Prevention, Cancer, Adolescent, Adult, Aged, Biomarkers, Tumor, Case-Control Studies, Child, Female, Genetic Predisposition to Disease, Germ-Line Mutation, Humans, Logistic Models, Male, Melanoma, Middle Aged, Odds Ratio, Polymorphism, Genetic, Receptor, Melanocortin, Type 1, Retrospective Studies, Skin Neoplasms, IMI Study Group, GEM Study Group, M-SKIP Study Group
Abstract

BackgroundGermline variants in the melanocortin 1 receptor gene (MC1R) might increase the risk of childhood and adolescent melanoma, but a clear conclusion is challenging because of the low number of studies and cases. We assessed the association of MC1R variants with childhood and adolescent melanoma in a large study comparing the prevalence of MC1R variants in child or adolescent patients with melanoma to that in adult patients with melanoma and in healthy adult controls.MethodsIn this retrospective pooled analysis, we used the M-SKIP Project, the Italian Melanoma Intergroup, and other European groups (with participants from Australia, Canada, France, Greece, Italy, the Netherlands, Serbia, Spain, Sweden, Turkey, and the USA) to assemble an international multicentre cohort. We gathered phenotypic and genetic data from children or adolescents diagnosed with sporadic single-primary cutaneous melanoma at age 20 years or younger, adult patients with sporadic single-primary cutaneous melanoma diagnosed at age 35 years or older, and healthy adult individuals as controls. We calculated odds ratios (ORs) for childhood and adolescent melanoma associated with MC1R variants by multivariable logistic regression. Subgroup analysis was done for children aged 18 or younger and 14 years or younger.FindingsWe analysed data from 233 young patients, 932 adult patients, and 932 healthy adult controls. Children and adolescents had higher odds of carrying MC1R r variants than did adult patients (OR 1·54, 95% CI 1·02-2·33), including when analysis was restricted to patients aged 18 years or younger (1·80, 1·06-3·07). All investigated variants, except Arg160Trp, tended, to varying degrees, to have higher frequencies in young patients than in adult patients, with significantly higher frequencies found for Val60Leu (OR 1·60, 95% CI 1·05-2·44; p=0·04) and Asp294His (2·15, 1·05-4·40; p=0·04). Compared with those of healthy controls, young patients with melanoma had significantly higher frequencies of any MC1R variants.InterpretationOur pooled analysis of MC1R genetic data of young patients with melanoma showed that MC1R r variants were more prevalent in childhood and adolescent melanoma than in adult melanoma, especially in patients aged 18 years or younger. Our findings support the role of MC1R in childhood and adolescent melanoma susceptibility, with a potential clinical relevance for developing early melanoma detection and preventive strategies.FundingSPD-Pilot/Project-Award-2015; AIRC-MFAG-11831.

Published
2019

6. Multistep tumor genetic evolution and changes in immunogenicity trigger immune-mediated disease eradication in stage IV melanoma: lessons from a single case

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, additional, Cossa, Mara, additional, Gargiuli, Chiara, additional, Busico, Adele, additional, Devecchi, Andrea, additional, Dugo, Matteo, additional, Bergamaschi, Laura, additional, De Cecco, Loris, additional, Cavalieri, Stefano, additional, Valeri, Barbara, additional, Tamborini, Elena, additional, Gallino, Gianfrancesco, additional, Del Vecchio, Michele, additional, Santinami, Mario, additional, Sensi, Marialuisa, additional, Rivoltini, Licia, additional, Di Guardo, Lorenza, additional, and Rodolfo, Monica, additional

Published
2024
Full Text
View/download PDF

7. Genome-wide association meta-analyses combining multiple risk phenotypes provide insights into the genetic architecture of cutaneous melanoma susceptibility

Author

Landi, Maria Teresa, Bishop, D. Timothy, MacGregor, Stuart, Machiela, Mitchell J., Stratigos, Alexander J., Ghiorzo, Paola, Brossard, Myriam, Calista, Donato, Choi, Jiyeon, Fargnoli, Maria Concetta, Zhang, Tongwu, Rodolfo, Monica, Trower, Adam J., Menin, Chiara, Martinez, Jacobo, Hadjisavvas, Andreas, Song, Lei, Stefanaki, Irene, Scolyer, Richard, Yang, Rose, Goldstein, Alisa M., Potrony, Miriam, Kypreou, Katerina P., Pastorino, Lorenza, Queirolo, Paola, Pellegrini, Cristina, Cattaneo, Laura, Zawistowski, Matthew, Gimenez-Xavier, Pol, Rodriguez, Arantxa, Elefanti, Lisa, Manoukian, Siranoush, Rivoltini, Licia, Smith, Blair H., Loizidou, Maria A., Del Regno, Laura, Massi, Daniela, Mandala, Mario, Khosrotehrani, Kiarash, Akslen, Lars A., Amos, Christopher I., Andresen, Per A., Avril, Marie-Françoise, Azizi, Esther, Soyer, H. Peter, Bataille, Veronique, Dalmasso, Bruna, Bowdler, Lisa M., Burdon, Kathryn P., Chen, Wei V., Codd, Veryan, Craig, Jamie E., Dębniak, Tadeusz, Falchi, Mario, Fang, Shenying, Friedman, Eitan, Simi, Sarah, Galan, Pilar, Garcia-Casado, Zaida, Gillanders, Elizabeth M., Gordon, Scott, Green, Adele, Gruis, Nelleke A., Hansson, Johan, Harland, Mark, Harris, Jessica, Helsing, Per, Henders, Anjali, Hočevar, Marko, Höiom, Veronica, Hunter, David, Ingvar, Christian, Kumar, Rajiv, Lang, Julie, Lathrop, G. Mark, Lee, Jeffrey E., Li, Xin, Lubiński, Jan, Mackie, Rona M., Malt, Maryrose, Malvehy, Josep, McAloney, Kerrie, Mohamdi, Hamida, Molven, Anders, Moses, Eric K., Neale, Rachel E., Novaković, Srdjan, Nyholt, Dale R., Olsson, Håkan, Orr, Nicholas, Fritsche, Lars G., Puig-Butille, Joan Anton, Qureshi, Abrar A., Radford-Smith, Graham L., Randerson-Moor, Juliette, Requena, Celia, Rowe, Casey, Samani, Nilesh J., Sanna, Marianna, Schadendorf, Dirk, Schulze, Hans-Joachim, Simms, Lisa A., Smithers, Mark, Song, Fengju, Swerdlow, Anthony J., van der Stoep, Nienke, Kukutsch, Nicole A., Visconti, Alessia, Wallace, Leanne, Ward, Sarah V., Wheeler, Lawrie, Sturm, Richard A., Hutchinson, Amy, Jones, Kristine, Malasky, Michael, Vogt, Aurelie, Zhou, Weiyin, Pooley, Karen A., Elder, David E., Han, Jiali, Hicks, Belynda, Hayward, Nicholas K., Kanetsky, Peter A., Brummett, Chad, Montgomery, Grant W., Olsen, Catherine M., Hayward, Caroline, Dunning, Alison M., Martin, Nicholas G., Evangelou, Evangelos, Mann, Graham J., Long, Georgina, Pharoah, Paul D. P., Easton, Douglas F., Barrett, Jennifer H., Cust, Anne E., Abecasis, Goncalo, Duffy, David L., Whiteman, David C., Gogas, Helen, De Nicolo, Arcangela, Tucker, Margaret A., Newton-Bishop, Julia A., Peris, Ketty, Chanock, Stephen J., Demenais, Florence, Brown, Kevin M., Puig, Susana, Nagore, Eduardo, Shi, Jianxin, Iles, Mark M., and Law, Matthew H.

Published
2020
Full Text
View/download PDF

8. Alterations in Plasma Lipid Profiles Associated with Melanoma and Therapy Resistance.

Author

Dei Cas, Michele, Ciniselli, Chiara Maura, Vergani, Elisabetta, Ciusani, Emilio, Aloisi, Mariachiara, Duroni, Valeria, Verderio, Paolo, Ghidoni, Riccardo, Paroni, Rita, Perego, Paola, Beretta, Giovanni Luca, Gatti, Laura, and Rodolfo, Monica

Subjects
BLOOD lipids, SATURATED fatty acids, UNSATURATED fatty acids, FATTY acid derivatives, LIPID metabolism, LIPIDS
Abstract

Dysfunctions of lipid metabolism are associated with tumor progression and treatment resistance of cutaneous melanoma. BRAF/MEK inhibitor resistance is linked to alterations of melanoma lipid pathways. We evaluated whether a specific lipid pattern characterizes plasma from melanoma patients and their response to therapy. Plasma samples from patients and controls were analyzed for FASN and DHCR24 levels and lipidomic profiles. FASN and DHCR24 expression resulted in association with disease condition and related to plasma cholesterol and triglycerides in patients at different disease stages (n = 144) as compared to controls (n = 115). Untargeted lipidomics in plasma (n = 40) from advanced disease patients and controls revealed altered levels of different lipids, including fatty acid derivatives and sphingolipids. Targeted lipidomics identified higher levels of dihydroceramides, ceramides, sphingomyelins, ganglioside GM3, sphingosine, sphingosine-1-phosphate, and dihydrosphingosine, saturated and unsaturated fatty acids. When melanoma patients were stratified based on a long/short-term clinical response to kinase inhibitors, differences in plasma levels were shown for saturated fatty acids (FA 16:0, FA18:0) and oleic acid (FA18:1). Our results associated altered levels of selected lipid species in plasma of melanoma patients with a more favorable prognosis. Although obtained in a small cohort, these results pave the way to lipidomic profiling for melanoma patient stratification. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma

Author

Huber, Veronica, Vallacchi, Viviana, Fleming, Viktor, Hu, Xiaoying, Cova, Agata, Dugo, Matteo, Shahaj, Eriomina, Sulsenti, Roberta, Vergani, Elisabetta, Filipazzi, Paola, De Laurentiis, Angela, Lalli, Luca, Di Guardo, Lorenza, Patuzzo, Roberto, Vergani, Barbara, Casiraghi, Elena, Cossa, Mara, Gualeni, Ambra, Bollati, Valentina, Arienti, Flavio, De Braud, Filippo, Mariani, Luigi, Villa, Antonello, Altevogt, Peter, Umansky, Viktor, Rodolfo, Monica, and Rivoltini, Licia

Subjects
Cancer patients -- Care and treatment, Immunotherapy -- Usage, MicroRNA -- Research, Suppressor cells -- Research, Treatment outcome -- Analysis, Cancer treatment, Tumors, Cell death, Infection, Melanoma, Health care industry
Abstract

The accrual of myeloid-derived suppressor cells (MDSCs) represents a major obstacle to effective immunotherapy in cancer patients, but the mechanisms underlying this process in the human setting remain elusive. Here, we describe a set of microRNAs (miR-146a, miR-155, miR-125b, miR-100, let-7e, miR-125a, miR-146b, miR-99b) that are associated with MDSCs and resistance to treatment with immune checkpoint inhibitors in melanoma patients. The miRs were identified by transcriptional analyses as being responsible for the conversion of monocytes into MDSCs ([CD14.sup.+][HLA-DR.sup.neg] cells) mediated by melanoma extracellular vesicles (EVs) and were shown to recreate MDSC features upon transfection. In melanoma patients, these miRs were increased in circulating [CD14.sup.+] monocytes, plasma, and tumor samples, where they correlated with the myeloid cell infiltrate. In plasma, their baseline levels clustered with the clinical efficacy of CTLA-4 or programmed cell death protein 1 (PD-1) blockade. Hence, MDSC-related miRs represent an indicator of MDSC activity in cancer patients and a potential blood marker of a poor immunotherapy outcome., IntroductionImmunotherapy with immune checkpoint inhibitors (ICIs) has achieved a remarkable improvement in overall survival (OS) in different tumor histologies, albeit the majority of patients display intrinsic resistance (1). The response [...]

Published
2018
Full Text
View/download PDF

12. miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

Author

Vergani, Elisabetta, Dugo, Matteo, Cossa, Mara, Frigerio, Simona, Di Guardo, Lorenza, Gallino, Gianfrancesco, Mattavelli, Ilaria, Vergani, Barbara, Lalli, Luca, Tamborini, Elena, Valeri, Barbara, Gargiuli, Chiara, Shahaj, Eriomina, Ferrarini, Marina, Ferrero, Elisabetta, Gomez Lira, Macarena, Huber, Veronica, Del Vecchio, Michele, Sensi, Marialuisa, Leone, Biagio Eugenio, Santinami, Mario, Rivoltini, Licia, Rodolfo, Monica, and Vallacchi, Viviana

Published
2020
Full Text
View/download PDF

14. Supplementary Figures S1, S2, S3, S4, S5 from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Author

Patel, Ankit, primary, Garcia, Lucia Fraile, primary, Mannella, Viviana, primary, Gammon, Luke, primary, Borg, Tiffanie-Marie, primary, Maffucci, Tania, primary, Scatolini, Maria, primary, Chiorino, Giovanna, primary, Vergani, Elisabetta, primary, Rodolfo, Monica, primary, Maurichi, Andrea, primary, Posch, Christian, primary, Matin, Rubeta N., primary, Harwood, Catherine A., primary, and Bergamaschi, Daniele, primary

Published
2023
Full Text
View/download PDF

15. Data from Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma

Author

Patel, Ankit, primary, Garcia, Lucia Fraile, primary, Mannella, Viviana, primary, Gammon, Luke, primary, Borg, Tiffanie-Marie, primary, Maffucci, Tania, primary, Scatolini, Maria, primary, Chiorino, Giovanna, primary, Vergani, Elisabetta, primary, Rodolfo, Monica, primary, Maurichi, Andrea, primary, Posch, Christian, primary, Matin, Rubeta N., primary, Harwood, Catherine A., primary, and Bergamaschi, Daniele, primary

Published
2023
Full Text
View/download PDF

16. Data from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Table 1 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Figure 1 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

20. Supplementary Table 5 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

21. Supplementary Table 4 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

22. Supplementary Figure 2 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

24. Supplementary Figure 3 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methods from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

26. Supplementary Table 3 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

27. Supplementary Methods, Figure 1 Legend , Tables 1-2 from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, primary, Ratti, Francesca, primary, Di Stasi, Delia, primary, Deho, Paola, primary, De Filippo, Annamaria, primary, Tragni, Gabrina, primary, Balsari, Andrea, primary, Carbone, Antonino, primary, Rivoltini, Licia, primary, Parmiani, Giorgio, primary, Lazar, Noureddine, primary, Perbal, Bernard, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

28. Supplementary Table 2 from Transcriptional Profiling of Melanoma Sentinel Nodes Identify Patients with Poor Outcome and Reveal an Association of CD30+ T Lymphocytes with Progression

Author

Vallacchi, Viviana, primary, Vergani, Elisabetta, primary, Camisaschi, Chiara, primary, Deho, Paola, primary, Cabras, Antonello D., primary, Sensi, Marialuisa, primary, De Cecco, Loris, primary, Bassani, Niccolò, primary, Ambrogi, Federico, primary, Carbone, Antonino, primary, Crippa, Federica, primary, Vergani, Barbara, primary, Frati, Paola, primary, Arienti, Flavio, primary, Patuzzo, Roberto, primary, Villa, Antonello, primary, Biganzoli, Elia, primary, Canevari, Silvana, primary, Santinami, Mario, primary, Castelli, Chiara, primary, Rivoltini, Licia, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

29. Supplementary Figure 1 from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, primary, Ratti, Francesca, primary, Di Stasi, Delia, primary, Deho, Paola, primary, De Filippo, Annamaria, primary, Tragni, Gabrina, primary, Balsari, Andrea, primary, Carbone, Antonino, primary, Rivoltini, Licia, primary, Parmiani, Giorgio, primary, Lazar, Noureddine, primary, Perbal, Bernard, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

30. Data from CCN3/Nephroblastoma Overexpressed Matricellular Protein Regulates Integrin Expression, Adhesion, and Dissemination in Melanoma

Author

Vallacchi, Viviana, primary, Daniotti, Maria, primary, Ratti, Francesca, primary, Di Stasi, Delia, primary, Deho, Paola, primary, De Filippo, Annamaria, primary, Tragni, Gabrina, primary, Balsari, Andrea, primary, Carbone, Antonino, primary, Rivoltini, Licia, primary, Parmiani, Giorgio, primary, Lazar, Noureddine, primary, Perbal, Bernard, primary, and Rodolfo, Monica, primary

Published
2023
Full Text
View/download PDF

31. Collecting ducts carcinoma: In depth exploration and biologically driven therapy (CICERONE).

Author

Verzoni, Elena, primary, De Braud, Filippo G., additional, Rametta, Alessandro, additional, Taglialatela, Ida, additional, Guadalupi, Valentina, additional, Stellato, Marco, additional, Giannatempo, Patrizia, additional, Claps, Melanie, additional, Bottiglieri, Achille, additional, Rodolfo, Monica, additional, Brunelli, Matteo, additional, Frigerio, Simona, additional, Mereu, Alessandro, additional, Vallacchi, Viviana, additional, Cerioli, Nicola, additional, Rivoltini, Licia, additional, and Sepe, Pierangela, additional

Published
2023
Full Text
View/download PDF

33. Extracellular vesicles in anti-tumor immunity

Author

Vergani, Elisabetta, primary, Daveri, Elena, additional, Vallacchi, Viviana, additional, Bergamaschi, Laura, additional, Lalli, Luca, additional, Castelli, Chiara, additional, Rodolfo, Monica, additional, Rivoltini, Licia, additional, and Huber, Veronica, additional

Published
2022
Full Text
View/download PDF

36. Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma

Author

Vergani, Elisabetta, primary, Beretta, Giovanni L., additional, Aloisi, Mariachiara, additional, Costantino, Matteo, additional, Corno, Cristina, additional, Frigerio, Simona, additional, Tinelli, Stella, additional, Dugo, Matteo, additional, Accattatis, Felice Maria, additional, Granata, Agnese, additional, Arnaboldi, Lorenzo, additional, Rodolfo, Monica, additional, Perego, Paola, additional, and Gatti, Laura, additional

Published
2022
Full Text
View/download PDF

37. 3D tumor explant as a novel platform to investigate therapeutic pathways and predictive biomarkers in cancer patients

Author

Rodolfo, M, Huber, V, Cossa, M, Gallino, G, Leone, B, Vallacchi, V, Rivoltini, L, Vergani, E, Rodolfo, Monica, Huber, Veronica, Cossa, Mara, Gallino, Gianfrancesco, Leone, Biagio E, Vallacchi, Viviana, Rivoltini, Licia, Vergani, Elisabetta, Rodolfo, M, Huber, V, Cossa, M, Gallino, G, Leone, B, Vallacchi, V, Rivoltini, L, Vergani, E, Rodolfo, Monica, Huber, Veronica, Cossa, Mara, Gallino, Gianfrancesco, Leone, Biagio E, Vallacchi, Viviana, Rivoltini, Licia, and Vergani, Elisabetta

Abstract

Immunotherapy with immune checkpoint inhibitors can induce durable clinical responses in different human malignancies but the number of responding patients remains globally modest. The limited therapeutic efficacy of ICI depends on multiple factors, among which the immune suppressive features of the tumor microenvironment play a key role. For this reason, experimental models that enable dissection of the immune-hostile tumor milieu components are required to unravel how to overcome resistance and obtain full-fledged anti-tumor immunity. Recent evidence supports the usefulness of 3D ex vivo systems in retaining features of tumor microenvironment to elucidate molecular and immunologic mechanisms of response and resistance to immune checkpoint blockade. In this perspective article we discuss the recent advances in patient-derived 3D tumor models and their potential in support of treatment decision making in clinical setting. We will also share our experience with dynamic bioreactor tumor explant culture of samples from melanoma and sarcoma patients as a reliable and promising platform to unravel immune responses to immune checkpoint inhibitors.

Published
2022

40. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup

Author

Bruno, William, Pastorino, Lorenza, Ghiorzo, Paola, Andreotti, Virginia, Martinuzzi, Claudia, Menin, Chiara, Elefanti, Lisa, Stagni, Camilla, Vecchiato, Antonella, Rodolfo, Monica, Maurichi, Andrea, Manoukian, Siranoush, De Giorgi, Vincenzo, Savarese, Imma, Gensini, Francesca, Borgognoni, Lorenzo, Testori, Alessandro, Spadola, Giuseppe, Mandalà, Mario, Imberti, Gianlorenzo, Savoia, Paola, Astrua, Chiara, Ronco, Anna Maria, Farnetti, Alessandra, Tibiletti, Maria Grazia, Lombardo, Maurizio, Palmieri, Giuseppe, Ayala, Fabrizio, Ascierto, Paolo, Ghigliotti, Giovanni, Muggianu, Marisa, Spagnolo, Francesco, Picasso, Virginia, Tanda, Enrica Teresa, Queirolo, Paola, and Bianchi-Scarrà, Giovanna

Published
2016
Full Text
View/download PDF

41. Liquid Biopsy and Radiological Response Predict Outcomes Following Discontinuation of Targeted Therapy in Patients with BRAF Mutated Melanoma

Author

Di Guardo, Lorenza, primary, Randon, Giovanni, additional, Corti, Francesca, additional, Vallacchi, Viviana, additional, Raimondi, Alessandra, additional, Fucà, Giovanni, additional, Bini, Marta, additional, Maurichi, Andrea, additional, Patuzzo, Roberto, additional, Gallino, Gianfrancesco, additional, Mattavelli, Ilaria, additional, Ruggeri, Roberta, additional, Angi, Martina, additional, Cossa, Mara, additional, Valeri, Barbara, additional, Cimminiello, Carolina, additional, Santinami, Mario, additional, Rivoltini, Licia, additional, Braud, Filippo, additional, Rodolfo, Monica, additional, and Vecchio, Michele Del, additional

Published
2021
Full Text
View/download PDF

42. Genetic Variants and Somatic Alterations Associated with MITF-E318K Germline Mutation in Melanoma Patients

Author

Vergani, Elisabetta, primary, Frigerio, Simona, additional, Dugo, Matteo, additional, Devecchi, Andrea, additional, Feltrin, Erika, additional, De Cecco, Loris, additional, Vallacchi, Viviana, additional, Cossa, Mara, additional, Di Guardo, Lorenza, additional, Manoukian, Siranoush, additional, Peissel, Bernard, additional, Ferrari, Andrea, additional, Gallino, Gianfrancesco, additional, Maurichi, Andrea, additional, Rivoltini, Licia, additional, Sensi, Marialuisa, additional, and Rodolfo, Monica, additional

Published
2021
Full Text
View/download PDF

44. Clinical genetic testing for familial melanoma in Italy: A cooperative study

Author

Bruno, William, Ghiorzo, Paola, Battistuzzi, Linda, Ascierto, Paolo A., Barile, Monica, Gargiulo, Sara, Gensini, Francesca, Gliori, Sara, Guida, Michele, Lombardo, Maurizio, Manoukian, Siranoush, Menin, Chiara, Nasti, Sabina, Origone, Paola, Pasini, Barbara, Pastorino, Lorenza, Peissel, Bernard, Pizzichetta, Maria Antonietta, Queirolo, Paola, Rodolfo, Monica, Romanini, Antonella, Scaini, Maria Chiara, Testori, Alessandro, Tibiletti, Maria Grazia, Turchetti, Daniela, Leachman, Sancy A., and Bianchi Scarrà, Giovanna

Published
2009
Full Text
View/download PDF

45. Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients

Author

Rinchai, Darawan, primary, Verzoni, Elena, additional, Huber, Veronica, additional, Cova, Agata, additional, Squarcina, Paola, additional, De Cecco, Loris, additional, Braud, Filippo, additional, Ratta, Raffaele, additional, Dugo, Matteo, additional, Lalli, Luca, additional, Vallacchi, Viviana, additional, Rodolfo, Monica, additional, Roelands, Jessica, additional, Castelli, Chiara, additional, Chaussabel, Damien, additional, Procopio, Giuseppe, additional, Bedognetti, Davide, additional, and Rivoltini, Licia, additional

Published
2021
Full Text
View/download PDF

46. Deregulated FASN Expression in BRAF Inhibitor-Resistant Melanoma Cells Unveils New Targets for Drug Combinations

Author

Stamatakos, Serena, primary, Beretta, Giovanni Luca, additional, Vergani, Elisabetta, additional, Dugo, Matteo, additional, Corno, Cristina, additional, Corna, Elisabetta, additional, Tinelli, Stella, additional, Frigerio, Simona, additional, Ciusani, Emilio, additional, Rodolfo, Monica, additional, Perego, Paola, additional, and Gatti, Laura, additional

Published
2021
Full Text
View/download PDF

48. Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients

Author

Huber, Veronica, primary, Di Guardo, Lorenza, additional, Lalli, Luca, additional, Giardiello, Daniele, additional, Cova, Agata, additional, Squarcina, Paola, additional, Frati, Paola, additional, Di Giacomo, Anna Maria, additional, Pilla, Lorenzo, additional, Tazzari, Marcella, additional, Camisaschi, Chiara, additional, Arienti, Flavio, additional, Castelli, Chiara, additional, Rodolfo, Monica, additional, Beretta, Valeria, additional, Di Nicola, Massimo, additional, Maio, Michele, additional, Del Vecchio, Michele, additional, de Braud, Filippo, additional, Mariani, Luigi, additional, and Rivoltini, Licia, additional

Published
2021
Full Text
View/download PDF

49. Additional file 3 of miR-146a-5p impairs melanoma resistance to kinase inhibitors by targeting COX2 and regulating NFkB-mediated inflammatory mediators

Author

Vergani, Elisabetta, Dugo, Matteo, Cossa, Mara, Frigerio, Simona, Di Guardo, Lorenza, Gallino, Gianfrancesco, Mattavelli, Ilaria, Vergani, Barbara, Lalli, Luca, Tamborini, Elena, Valeri, Barbara, Gargiuli, Chiara, Shahaj, Eriomina, Ferrarini, Marina, Ferrero, Elisabetta, Gomez Lira, Macarena, Huber, Veronica, Del Vecchio, Michele, Sensi, Marialuisa, Leone, Biagio Eugenio, Santinami, Mario, Rivoltini, Licia, Rodolfo, Monica, and Vallacchi, Viviana

Abstract

Additional file 2: Supplementary Fig. S1. Altered miR-146a expression influences BRAF/MEKi sensitivity and apoptosis in melanoma. A) Boxplots representing IC50 values of 6 matched PLX4032-resistant (R) and sensitive (S) melanoma cell lines to PLX4032 (vemurafenib), BRAFi (dabrafenib), MEKi (trametinib), to the combined treatment BRAF/MEKi, and to sTRAIL-induced apoptosis. B) Inverse correlation between miR-146a expression levels and IC50 values of PLX4032, BRAFi and MEKi in melanoma cell lines (Spearman analysis). C) Forced expression of miR-146a (+m-miR-146a) in LM16R cell line and in LM69 and LM70 short term cultures increased the effects of PLX4032 treatment as shown by reduced cell growth and increased cell cytotoxicity and apoptosis, evaluated by CCK8, LDH and caspase 8 and 3/7 activity. D) Inhibition of miR-146a expression (i-miR-146a) in LM16 cells increased cell proliferation and decreased the release of LDH and the apoptosis rate as evaluated by CCK8, LDH and caspase 3/7 activity. E) Overexpression of miR-146a (m-miR-146a) upon PLX4032, BRAF/MEKi and sTRAIL treatments in LM47R cells increased cell cytotoxicity and apoptosis, as evaluated by LDH and caspase 8 and 3/7 activity. Data are plotted compared to scrambled control. *: p < 0.05, **: p < 0.01, ***: p < 0.0001 by Student’s unpaired t test. Supplementary Fig. S2. COX2 inhibition increases sensitivity to PLX4032 and to BRAF/MEKi and reduces PGE2 release. A) Relative luciferase activity after co-transfection of PTGS2 3’UTR luciferase reporter vector or control vector with miR-146a mimic or mimic negative control. Experiment was performed in LM16R cells. B) Inverse correlation between miR-146a expression levels and IC50 values of PLX4032 in melanoma cell lines (Spearman analysis). C) Western blot analyses showing downregulation of COX2 after transfection with siRNA against COX2 (siCOX2) compared to scrambled control (S). COX2 protein levels were downregulated to 15%, as determined by quantification of the signal and expressed as the ratio of COX2/Actin intensity. Experiment was performed with LM47R cells. D) Silencing of COX2 by siRNA transfection enhanced cell growth inhibition and increased cell cytotoxicity and apoptosis upon treatment with PLX4032 compared to scrambled control. E) PGE2 release in culture supernatants following 24 h treatment with the COX2 inhibitors celecoxib and NS398, alone or in combination with BRAF/MEKi. F) Combined treatment with celecoxib increased cell growth inhibition and cytotoxicity by PLX4032. ●: interaction index = 1. G) Dose-dependent effect of celecoxib alone (5, 10, 20, 40, 50 and 80 μM) and combined with PLX4032 (3 μM) on cell growth. ●: interaction index = 1 at the dose of 50 μM of celecoxib combined with PLX4032. P values were calculated by Student’s unpaired t test in A, D and F, by one-way ANOVA followed by Bonferroni correction in E, and by two-way ANOVA followed by Bonferroni correction in G. *: p < 0.05, **: p < 0.01, ***: p < 0.0001. Supplementary Fig. S3. miR-146a expression levels are inversely correlated with levels of target genes. Analysis of correlation between miR-146a expression and its target genes EGFR, CCL2 and BCL2L1 in metastatic melanoma specimens. The rp and p values resulting from Pearson analysis are shown. Supplementary Fig. S4. Dynamic culture in bioreactor preserves TME architecture of 3D tumor explants. Representative histological images of H&E-stained 3D tumor sections after 3 days culture in bioreactor. The marked areas in the left panels are shown at higher magnification in the right panels to display the preserved cellularity and tumor tissue histo-architecture. Scale bar 80 μM. Supplementary Fig. S5. miR-146a overexpression increases drug sensitivity in 3D cultures of tumor explants. A) Modulation of direct and indirect miR-146a target genes upon transfection of miR-146a mimic (m-miR-146a) compared to scrambled-transfected control (S) in 3D cultures of BRAF-mutated melanoma tumors from naïve patients. AU: arbitrary units. B) Decreased staining for Ki67 and pERK proliferating cells and increased Caspase 3 positive cells in 3D cultures upon treatment with BRAF/MEKi and transfection with miR-146a (m-miR-146a) or scrambled control (S). Scale bar 10 um.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results